Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PaxMedica, Inc. (PXMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0515-0.3285 (-13.80%)
At close: 03:59PM EST
2.1700 +0.12 (+5.78%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.3800
Open2.4000
Bid2.0600 x 1100
Ask2.2400 x 800
Day's Range1.9600 - 2.4000
52 Week Range1.3600 - 10.4800
Volume257,340
Avg. Volume1,789,357
Market Cap24.574M
Beta (5Y Monthly)N/A
PE Ratio (TTM)17.10
EPS (TTM)0.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PXMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PaxMedica, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

    TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced it will be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City. Zachar

  • GlobeNewswire

    PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

    -Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for

  • GlobeNewswire

    PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

    -PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and rep

Advertisement
Advertisement